DocMorris stock slipped 1.7% on the day even after the online pharmacy posted stronger-than-expected first-half results and raised its full-year outlook. The stock initially jumped by double digits in pre-market trading on Tradegate, but much of those gains were given back as investors locked in profits.
On the top line, DocMorris reported external revenue for H1 2026 up 12.5% in local currency, reaching CHF 627.8 million. The company also showed progress on profitability, with its adjusted EBITDA loss shrinking by CHF 17.9 million year-on-year to CHF -10.9 million. Management said that this improvement provides additional comfort that achieving EBITDA breakeven in the second half of 2026 remains within reach.
DocMorris tightened its full-year adjusted EBITDA guidance to a loss range of CHF -10 million to CHF -17.5 million, narrowing the prior range that extended to a loss of up to CHF -25 million. The adjusted guidance reflects management’s updated view based on first-half performance.
Investors treating the print cautiously is partly explained by market dynamics. DocMorris had already issued a stronger-than-expected Q2 revenue update in mid-July, so much of the market had anticipated a positive formal report. That sequence - an early rally followed by profit-taking - is consistent with a "buy the rumour, sell the news" pattern, where expectations built into the share price ahead of the official results.
The headline EBITDA figure also included CHF 7.6 million in one-off extraordinary charges. Those costs are associated with the rollout of DocMorris’s "AI-First" strategy and the closure of its Ludwigshafen facility. The inclusion of these items in the reported EBITDA added nuance for investors assessing the underlying operating performance.
On the competitive front, Redcare Pharmacy moved higher during the session, benefiting from the positive read-through of DocMorris’s raised guidance for the European online pharmacy segment. Broader market conditions were largely neutral, with U.S. indices trading near flat and no clear Swiss-specific macro catalyst identified for the trading day.
Viewed in context, the price pullback does not appear to represent a rejection of DocMorris’s improving fundamentals. Rather, it reads as a consolidation after a sharp rebound from a 52-week low of CHF 3.92, with the market having priced in much of the favourable news before the formal release.
Analytical note - From a product and strategy perspective, the reported revenue growth and narrowed EBITDA loss signal that customer adoption and unit economics are moving in a positive direction, while the one-off investments tied to the AI-First rollout and facility closure illustrate strategic repositioning costs that temporarily weigh on reported profitability.